ISA201 / ISA Pharma - LARVOL DELTA

Intradermal vaccination of HPV-16 E6 synthetic peptides conjugated to an optimized Toll-like receptor 2 ligand shows safety and potent T cell immunogenicity in patients with HPV-16 positive (pre-)malignant lesions. (PubMed, J Immunother Cancer) - P1 | "Amplivant-conjugated SLPs can safely be used as an intradermal therapeutic vaccine to induce robust HPV16-specific T cell immunity in patients previously treated for HPV16 positive (pre-) malignancies. Increased vaccine dose was associated with a higher number of mild adverse events and with stronger systemic T cell immunity."

Journal • Dermatitis • Immunology • Inflammation • Oncology • TLR2

[VIRTUAL] Phase I trial to determine safety and immunogenicity of amplivant, a synthetic toll-like receptor 2 ligand, conjugated to two HPV16 E6 synthetic long peptides. (ASCO 2021) - P1 | "This first-in-human study showed that AV conjugated to SLPs can safely be used as an intradermal therapeutic vaccine . AV-conjugated HPV16-SLP was able to induce robust HPV16-specific T-cell immunity in patients treated for HPV16 positive (pre-) malignancies without any other vaccine adjuvant or formulation . Increase in dose resulted in both a higher number of mild adverse events as well as stronger T-cell immunity."

Clinical • P1 data • Immunology • Inflammation • Oncology • IFNG

Hespecta Vaccination in HPV+ Tumors or Malignant Lesions (clinicaltrials.gov) - P1; N=25; Completed; Sponsor: Leiden University; Recruiting ➔ Completed; Trial completion date: Dec 2017 ➔ Mar 2020; Trial primary completion date: Dec 2017 ➔ Mar 2020

Clinical • Trial completion • Trial completion date • Trial primary completion date • Oncology